Primary Biliary Cholangitis — A New Name and a New Treatment
Author:
- 18 August 2016
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (7) , 685-687
Abstract
Primary biliary cholangitis, previously called primary biliary cirrhosis, is a cholestatic autoimmune liver disease that is marked by the progressive lymphocytic destruction of the smallest intralobular bile ducts.1,2 In the absence of effective therapy, it progresses inexorably to cirrhosis and liver failure.Ursodiol, a hydrophilic bile acid with an excellent safety profile, was approved by the Food and Drug Administration (FDA) in 1988 for the dissolution of gallstones. On the basis of early promising data in the management of primary biliary cholangitis and the unmet clinical need, the FDA granted ursodiol orphan status in 1991 for the management of . . .Keywords
This publication has 9 references indexed in Scilit:
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisNew England Journal of Medicine, 2016
- Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up StudyGastroenterology, 2014
- Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcomeJournal of Hepatology, 2011
- American Association for the Study of Liver Diseases Endpoints Conference: Design and Endpoints for Clinical Trials in Primary Biliary CirrhosisHepatology, 2010
- EASL Clinical Practice Guidelines: Management of cholestatic liver diseasesJournal of Hepatology, 2009
- Primary biliary cirrhosis # †Hepatology, 2009
- Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosisHepatology, 2008
- Ursodeoxycholic acid in the treatment of primary biliary cirrhosisGastroenterology, 1994
- A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary CirrhosisNew England Journal of Medicine, 1991